Hua Medicine, a China-based drug development company with a focus on developing a global first-in-class oral drug for the treatment of Type 2 diabetes, successfully completed its initial public offering, or IPO, and listing on the Hong Kong Stock Exchange.
Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, announced Wenjie Xu, an experienced sales & marketing veteran in China, joins Hua Medicine as VP, Head of Commercial Strategy and Marketing
Hua Medicine, a clinical-stage drug development company developing novel therapies for the treatment of Type 2 diabetes, announced the closing of a combined Series D & Series E financing of US$ 117.4 million.
Mr. George Lin, a healthcare veteran brings with him over 20 years of investment banking and legal experience working with numerous private and public companies globally.
Hua Medicine, a leading clinical stage biotech company in Shanghai, announced today positive results in the first-ever successful Phase 2 monotherapy trial of a novel drug class called glucokinase activators (GKA).
The Phase II clinical trial was initiated exactly one year ago on September 22, 2015 with 258 Chinese Type 2 Diabetes patients participating in the drug treatment study.
Copyright © 2019 Hua Medicine, All Rights Reserved沪ICP备14036654号